A Study of GLB-001 in Patients With Myeloid Malignancies

Abroad (travel likely)RecruitingPHASE1

Conditions

Polycythemia Vera · Essential Thrombocythemia · Myelofibrosis · Myelodysplastic Syndromes · Acute Myeloid Leukemia · Myeloid Malignancy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui, China
Contact: Study coordinator (Xiaoyu Zhu, MD) · 86-0551-62283160
China-Japan Friendship Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Zhenling Li, MD) · 86-010-84205566
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
Contact: Study coordinator (Li Wang, MD) · 86-023-68811360
The First Hospital of Hebei Medical Universtiy, Shijiazhuang, Hebei, China
Contact: Study coordinator (Qingchi Liu, MD) · 86-0311-85917000
Henan Cancer Hospital, Zhengzhou, Henan, China
Contact: Study coordinator (Hu Zhou, MD) · 86-0371-65587320
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
Contact: Study coordinator (Xuelan Zuo, MD) · 86-027-67812888
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Contact: Study coordinator (Miao Miao, MD) · 86-0512-65223637
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Contact: Study coordinator (Fei Li, MD) · 86-0791-88603000
Sheng Jing Hospital of China Medical Universtiy, Shenyang, Liaoning, China
Contact: Study coordinator (Wei Yang, MD) · 86-024-96615
Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Wei Wang, MD) · 86-021-52889999
Guoying Cao, MD (Sub-investigator)
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (Lei Zhang, MD) · 86-022-23909240
The Second Hospital of Tianjin Medical Universtiy, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (Jie Bai, MD) · 86-022-88328832
The First Affilicated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Contact: Study coordinator (Hongyan Tong, MD) · 86-0571-87236114
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
Contact: Study coordinator (Songfu Jiang, MD) · 86-0577-55578532

Study leads

Gang Lu, Ph.D.
Study Director
Hangzhou GluBio Pharmaceutical Co., Ltd.

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Acute Myeloid Leukemia · Essential Thrombocythemia · Myelodysplastic Syndrome

Abroad (travel likely)RecruitingPHASE2

Seattle, United States

Two Step Haplo With Radiation Conditioning

Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Adult T-Cell Leukemia/Lymphoma

Abroad (travel likely)RecruitingPHASE2

Philadephia, United States

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Myelofibrosis; Anemia · Anemia · Myelofibrosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Gilbert, United States · Duarte, United States

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Primary Myelofibrosis (PMF) · Post-polycythemia Vera Myelofibrosis (Post-PV MF) · Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Abroad (travel likely)RecruitingPHASE1

Kamogawa, Japan · Sapporo, Japan